Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Babjuk, 2011, EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: the 2011 update, Eur Urol, 59, 997, 10.1016/j.eururo.2011.03.017

Brausi, 2011, A review of current guidelines and best practice recommendations for the management of non muscle-invasive bladder cancer by the International Bladder Cancer Group, J Urol, 186, 2158, 10.1016/j.juro.2011.07.076

Morales, 1976, Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J Urol, 116, 180, 10.1016/S0022-5347(17)58737-6

Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 168, 1964, 10.1016/S0022-5347(05)64273-5

Lamm, 2000, Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA–T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5

Malmstrom, 2009, An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non–muscle-invasive bladder cancer, Eur Urol, 56, 247, 10.1016/j.eururo.2009.04.038

Böhle, 2004, Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression, Urology, 63, 682, 10.1016/j.urology.2003.11.049

Böhle, 2003, Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity, J Urol, 169, 90, 10.1016/S0022-5347(05)64043-8

Sylvester, 2010, Eur Urol, 57, 766, 10.1016/j.eururo.2009.12.024

Van der Meijden, 2001, J Urol, 166, 476, 10.1016/S0022-5347(05)65966-6

Vegt, 1997, Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of EORTC protocol 30911, J Urol, 157, 1246, 10.1016/S0022-5347(01)64936-X

Colombel, 2006, The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled multicenter study, J Urol, 176, 935, 10.1016/j.juro.2006.04.104

Martínez-Piñeiro, 2002, Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacillus Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer, BJU Int, 89, 671, 10.1046/j.1464-410X.2002.02722.x

Martínez-Piñeiro, 2005, Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrence and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial, J Urol, 174, 1242, 10.1097/01.ju.0000173919.28835.aa

Ojea, 2007, A multicentre, randomized prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) vs mitomycin C, Eur Urol, 52, 1398, 10.1016/j.eururo.2007.04.062

Oddens, 2013, Final results of an EORTC-GU cancer group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years maintenance, Eur Urol, 63, 462, 10.1016/j.eururo.2012.10.039

Johnson, 2013, Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical bacillus Calmette-Guérin treatment, J Urol, 189, 1268, 10.1016/j.juro.2012.10.070

Mack, 2001, The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder, J Urol, 165, 401, 10.1097/00005392-200102000-00011

van der Meijden, 2003, Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial, Eur Urol, 33, 429, 10.1016/S0302-2838(03)00357-9

Witjes, 2008, Clinical practice recommendations for the prevention and management of intravesical therapy–associated adverse events, Eur Urol Suppl, 7, 667, 10.1016/j.eursup.2008.08.001